Clinical trial Recruiting at 2 sites Observational Ages 18 and up

Daily activity and heart outcomes in people with chronic heart failure

Official title: Assessment of Physical Activity and Cardiovascular Outcomes in Patients With Chronic Heart Failure

Run by LMU Klinikum · NCT07460531 · Data updated 2026-11-12

We test whether tracking daily activity with pedometers and questionnaires can help predict heart-related events and hospital visits in adults with chronic heart failure.

More Heart Failure trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2000 (estimated)
SponsorLMU Klinikum
Academic / other
Locations2 sites (Munich, Bavaria and 1 other locations)
StatusRecruiting
StartedFebruary 1, 2025
Main results expectedDecember 31, 2030
Study endsJune 30, 2031
Registry record updatedMarch 11, 2026
Trial IDNCT07460531 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with chronic heart failure (NYHA II–IV) who have had NT‑proBNP >600 pg/ml, own a pedometer or activity device, and are physically able to walk would be ideal candidates.

Probably not a fit

Patients who cannot ambulate, lack a pedometer or reliable phone access, or who were hospitalized for heart failure within the past three months are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

SOPHIE is a prospective, multicentre observational cohort enrolling 2,000 adults with chronic heart failure. At baseline participants complete validated physical activity questionnaires (GPAQ, IPAQ, KCCQ) and provide seven-day step counts from consumer pedometers or wearable devices. Follow-up occurs every six months by telephone to repeat activity assessments and to record cardiovascular events, hospitalisations, and patient-reported outcomes. Inclusion requires prior NT-proBNP >600 pg/ml, NYHA II–IV status across any ejection fraction category, age ≥18, and ownership of a pedometer, while exclusion includes conditions preventing activity or heart-failure hospitalization within the last three months.

Why it matters

Potential benefit: If successful, the approach could help clinicians identify higher-risk patients earlier and support activity-based monitoring to reduce hospitalisations.

How similar studies have gone: Previous observational studies have linked wearable activity measures and questionnaire scores to outcomes in heart failure, but large prospective cohorts using consumer pedometers remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Heart failure NT-proBNP \>600 pg/ml (at least once in the history) NYHA-Class II-IV HFrEF - heart failure with reduced ejection fraction; LVEF ≤40% or HFmrEF - heart failure with mildly reduced ejection fraction; LVEF 41% - 49% or HFpEF - heart failure with preserved ejection fraction; LVEF ≥50%
* Age ≥18 years old
* Willingness to participate in the study, confirmed by a signed informed consent form
* Ownership of a pedometer (e.g. smartwatch, activity tracker, smartphone-app, analogical pedometer)

Exclusion Criteria:

* Disease or disability that prevents physical activity
* Hospitalisation due to heart failure within the last three months

Where it's running

  • LMU University Hospital
    Munich, Bavaria, Germany
    Recruiting
  • Central Hospital of Bolzano
    Bolzano, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.